ReviewMediators of inflammation2013
Glucocorticosteroid in treatment of severe pneumonia.
Review in Mediators of inflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis.Medicine · 2019Pooled it
- Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers.Drug design, development and therapy · 2017Trial
- Xuebijing injection in the treatment of severe pneumonia: study protocol for a randomized controlled trial.Trials · 2016Trial
- Development and validation of machine learning-based prediction model for severe pneumonia: A multicenter cohort study.Heliyon · 2024Article
- Critical Illness-Related Corticosteroid Insufficiency (CIRCI) Among Patients with COVID-19 at a Tertiary Hospital: Clinical Characteristics and Outcomes.Journal of the ASEAN Federation of Endocrine Societies · 2023Article
- N-myc and STAT interactor is a novel biomarker of severity in community-acquired pneumonia: a prospective study.Respiratory research · 2022Observational
- Tackling SARS-CoV-2: proposed targets and repurposed drugs.Future medicinal chemistry · 2020Review
- COVID-19 and kidney transplantation: an Italian Survey and Consensus.Journal of nephrology · 2020Article
- Corticosteroids in Acute Lung Injury: The Dilemma Continues.International journal of molecular sciences · 2019Review
- Advances in severe community-acquired pneumonia.Chinese medical journal · 2019Article
- Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study.Intensive care medicine · 2018Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Airway diseases such as pneumonia constitute a major health burden on a global scale; untreated pneumonia may develop to severe pneumonia and consequently lead to to fatal episodes of mortality and morbidity. The balance between inflammatory mediators is key for the outcome of the pulmonary infection; elimination of invading pathogen was marked by the release of cytokines and other inflammatory mediators from alveolar macrophages and glucocorticoid steroids (GCs) acting on the inflammatory component. Treatments of severe pneumonia with GCs have been developing for years with inconclusive results. In many cases GCs have been administered empirically without clinical evidence. Recent studies assess beneficial impact on treatment of severe pneumonia by suggesting specific dosage, period of administration, and tapered dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.